查看購物車
  • Simplified Chinese
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1827419

2025-2032 年全球抗肥胖藥物市場預測（依產品類型、劑型、給藥途徑及最終用戶分類）

Anti-Obesity Drugs Market by Product Type, Dosage Form, Route Of Administration, End User - Global Forecast 2025-2032
出版日期: | 出版商: 360iResearch | 英文 188 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2032 年，減重藥物市場規模將成長至 70.7 億美元，複合年成長率為 7.06%。

主要市場統計數據
基準年2024年 40.9億美元
預計2025年 43.8億美元
預測年份：2032年 70.7億美元
複合年成長率（%） 7.06%

當代抗肥胖治療環境的策略方向，重點關注臨床進展、相關人員的期望以及持續計畫成功的營運要求

減重藥物治療領域已從一個小眾臨床主題發展成為生物製藥公司、支付者和醫療保健系統的主流策略重點。新型腸促胰島素藥物和聯合治療正在重塑人們對持續減重和代謝改善的臨床期望，並重新激發了商業、臨床和監管相關人員的興趣。這種轉變要求經營團隊將快速的治療創新與長期安全性、依從性策略和成本效益等實際因素相協調。

臨床醫生擴大將肥胖視為一種慢性疾病，需要持續的藥物介入和生活方式的改變。為此，保險公司推出了強調療效和基於價值的合約的有條件承保框架。同時，製造和分銷生態系統正在適應注射劑和複雜生物製藥的獨特需求。這些交叉力量共同為尋求推出和擴大抗減肥藥的組織創造了機遇，也帶來了複雜性。

本引言將重點放在創新、可及性和系統級準備的交匯，構成執行摘要的其餘部分。下文將概述不斷變化的治療格局、關稅相關的供應鏈影響、細分驅動的商業性考慮、區域動態、競爭格局、可行建議、調查方法以及決策者的最終優先事項。每個要素旨在為策略規劃提供訊息，識別營運風險，並優先考慮短期和中期的高影響力干預措施。

科學突破、不斷發展的報銷模式以及新的交付方式如何重新定義減肥藥的競爭動態和護理途徑

在臨床突破和支付模式演變的推動下，減肥藥物市場格局正在改變。腸促胰島素生物學和雙促效劑平台的突破顯著提升了療效基準，改變了處方模式，並提高了人們對減肥和持續代謝益處的期望。這種科學動能正在引發一系列連鎖反應，包括適應症擴大、仿單標示外適應症考慮以及競爭加劇，從而重塑了藥物的生命週期規劃和上市策略。

同時，報銷框架也在改變。如今，付款方策略越來越強調長期療效、分級診療以及將報銷與績效指標掛鉤的新型合約模式。健康系統正在重新調整護理路徑，將藥物治療納入多學科肥胖管理項目，從而影響門診、醫院和居家照護機構的用藥模式。此外，注射劑型的激增也帶來了新的物流和患者教育需求，製造商必須滿足這些需求，以確保患者依從性和實際療效。

這些轉變將要求企業從以產品為中心的產品發布模式轉向整合的生態系統，將臨床證據產生、病患支援服務和動態定價方法連結起來。能夠展現持續成果、營運可擴展分銷模式、並與付款方和供應商有效合作以降低長期取得門檻的企業，將實現策略差異化。

分析 2025 年美國關稅調整將如何影響整個減肥藥生態系統，包括採購、製造重組、付款人覆蓋範圍和准入策略

2025年美國關稅調整對整個抗肥胖療法價值鏈產生了連鎖反應，加劇了依賴進口零件的脆弱性，並改變了最終產品的成本計算。生技藥品和複雜小分子的原料採購通常跨越多個邊境。半成品的關稅增加了到岸成本，促使企業重新評估其供應商佈局。為此，採購團隊加快了供應商多元化，並考慮簽訂遠期合約以對沖投入價格波動。

製造商也重新評估了其全球製造佈局，並探索了近岸外包方案，以降低關稅導致的價格波動風險。此類策略調整對生產力計畫、技術轉移時間表和監管備案有重大影響，因為轉移生產基地或更改供應商名單需要耗時檢驗，甚至可能接受衛生部門的檢查。對於對低溫運輸完整性和前置作業時間敏感的高需求注射藥物而言，此類延誤可能會推遲上市，並使庫存規劃複雜化。

支付方和供應商透過收緊處方集配置和加強使用控制來應對不斷上漲的產品成本。同時，一些醫療保健機構專注於節省成本的替代方案，例如非藥物干預措施和傳統口服藥物。同時，擁有垂直整合供應鏈和國內生產能力的製造商享有相對優勢，確保了供應的連續性和更彈性價格設定。簡而言之，主導壓力強化了供應鏈彈性、監管敏捷性和積極的相關人員參與的策略價值，以維持病患可及性和商業性發展勢頭。

將產品形態、劑型、給藥途徑和最終用戶設定與臨床和商業性機會聯繫起來的詳細細分見解

基於細分市場的分析揭示了在治療方案、劑量、給藥途徑和最終用戶載體方面存在的差異化機會和限制，這些機會和限制將影響產品組合和商業策略。按產品類型分類，GLP-1促效劑和雙重促效劑因其高效性而推動臨床醫生的需求，而納曲酮-安非他酮、奧利司他、芬特明-托吡酯和SGLT2抑制劑等成熟藥物仍然適用於特定患者群體和合併症主導的處方。由於作用機制和安全性各異，治療順序、合併策略和禁忌症管理仍是臨床訊息的核心。

劑型考量對患者接受度和供應鏈設計有顯著影響。注射劑市場（包括預填充筆和管瓶）需要強大的低溫運輸物流和全面的病患教育計劃，以最佳化依從性。膠囊和片劑在處方便利性和便利性方面具有優勢，當成本或患者偏好限制注射的使用時，這一點至關重要。因此，生命週期管理必須兼顧臨床差異化和實際給藥限制，以最大限度地提高不同環境的藥物吸收率。

給藥途徑進一步加深了商業和臨床策略的層次。注射途徑，包括自動注射器、預填充注射筆和管瓶，需要在護理師和藥劑師培訓、遠端監控支援以及設備人體工學方面進行投資，以減少給藥障礙。鼻腔和口服途徑提供差異化的價值提案，例如快速起效和便利性，可以擴大對注射猶豫患者的覆蓋範圍。最後，最終用戶細分為診所、居家醫療和醫院，會影響分銷選擇、通路經濟效益以及病患支援服務的設計。雖然診所和醫院門診計畫通常是急性病例的早期採用者，但居家照護服務正成為慢性治療順從性和長期保留的關鍵。

臨床應用、付款人要求和監管複雜性的區域差異導致美洲、歐洲、中東和非洲地區以及亞太地區採用不同的准入策略

每個地區的動態呈現不同的臨床、監管和商業模式，需要獨特的市場進入和規模化策略。在美洲，強大的支付方影響力、大規模的臨床應用以及患者對有效療法的旺盛需求，共同創造了一個競爭激烈的環境，其中長期療效和成本效益的證據至關重要。能夠與基於價值的合約和患者支援基礎設施合作的製造商，很可能在專科診所和更廣泛的門診網路中獲得關注。

歐洲、中東和非洲是一個多元化的地區，其特點是監管環境、報銷實務和臨床基礎設施水準存在差異。國家醫療保健系統和當地支付方通常要求更嚴格的衛生技術評估和比較有效性數據，因此，針對特定區域的證據生成和早期的衛生技術評估 (HTA) 參與尤為重要。在公共覆蓋範圍有限的市場中，私人支付和基於診所的模式可能有助於推動早期採用，而與當地經銷商的夥伴關係可以最佳化可及性。

亞太地區的特點是快速的都市區滲透、多樣化的監管時間表以及公立和私立支付機構結構的混合。高人口密度和代謝性心臟疾病日益成長的盛行率使該地區具有重要的戰略意義，但製造商必須應對價格敏感性、不同的處方習慣以及日益激烈的本地競爭。所有地區都需要採取一致的監管協調方法、本地臨床數據生成和患者支持生態系統，才能將臨床前景轉化為永續的可近性和療效。

競爭動態和企業策略將透過證據生成、供應彈性和綜合患者解決方案決定抗減肥藥的長期領導地位

減肥藥領域的競爭格局由成熟製藥公司和創新生物技術公司共同塑造。市場領導企業正利用深厚的臨床開發能力來擴展適應症並建立頭對頭證據基礎，而新參與企業則專注於差異化機制、設備創新和整合的患者支持提案。對於尋求加速產品線成熟度並擴大商業性覆蓋範圍的公司來說，策略夥伴關係、共同開發契約和收購是常見的做法。

將可靠的結果數據與可擴展的患者服務相結合的公司，很可能在付款人談判和供應商招募方面擁有競爭優勢。擁有強大製造地和供應鏈冗餘的公司，在需求波動期間，更能維持供應連續性。同時，投資於設備人體工學、數位依從性工具和多學科護理模式的公司，將更有能力應對現實世界中在有效性和患者留存方面的挑戰。

智慧財產權策略和生命週期管理計畫也將決定公司的長期定位，尤其是在生物相似藥和小分子藥物競爭對手進入市場的情況下。積極主動地管理監管排他性、器械專利和配方改進可以延長公司的商業性可行性。最終，那些將臨床差異化與卓越營運和以付款人為主導的證據相結合的公司，將在將科學前景轉化為持續的患者可及性方面佔據領先地位。

為製造商和相關人員提供具有影響力且可行的建議，以確保獲得藥物、加強供應鏈並最大化現實世界的治療價值

產業領導者應優先考慮一系列可行的干涉措施，將臨床前景轉化為持續的商業性成果。首先，投資制定分階段的證據產生計劃，將關鍵臨床試驗數據與旨在證明持續代謝和生活品質益處的務實真實世界試驗相結合。儘早與付款方和健康技術管理局 (HTA) 機構合作，協調終點和證據包，可以減少下游的可及性摩擦。

第二，透過多元化供應商、加快替代設施的資格認證以及在適當情況下考慮近岸外包來增強供應鏈的韌性，以降低海關和物流風險。對於注射藥物，同時投資低溫運輸能力和庫存管理系統至關重要。第三，設計患者支持模式，以解決初始用藥和長期用藥依從性問題。進行多通路注射技術教育，利用數位化用藥依從性工具，並與診所和居家照護機構合作，以確保護理的連續性。

第四，採用靈活的商業模式，例如基本契約、階梯定價和針對特定適應症的處方策略。將通訊和病人歷程與給藥途徑和劑型偏好相結合，並最佳化設備設計以減少摩擦。最後，在分銷、遠端醫療整合和本地證據生成方面開展策略合作，以加速異質區域市場的可及性。同時執行這些行動將顯著提高持續採用和付款人協調的可能性。

嚴格的多方法研究框架，結合相關人員訪談、監管調查、臨床證據綜合和情境分析，得出策略結論

本執行摘要所依據的研究結合了多種方法，以確保獲得均衡且可操作的見解。我們與內分泌和肥胖臨床醫生、醫院藥屋主任、付款方政策主導者以及供應鏈高管進行了初步定性訪談，以確定近期營運風險和應用促進因素。我們還系統地審查了監管和臨床指南文件以及公共臨床試驗註冊中心，以檢驗影響治療定位、安全訊號和覆蓋範圍討論的終點事件。

定量綜合分析從公共衛生數據、臨床試驗結果和產品核可中提取處方趨勢，以繪製採用軌跡並識別以管道為中心的需求訊號。運用情境規劃技術評估不同成本和供應條件下關稅、生產遷移時間表以及潛在付款人反應的影響。最後，由商業、醫學和監管專家參與的跨職能研討會指導制定切實可行的建議，以平衡臨床嚴謹性與商業性現實。

品質保證措施包括跨多個資料來源的三角測量、關鍵發現的專家檢驗以及供應鏈假設的敏感度分析。最終的調查方法優先考慮透明度、可複製性和策略相關性，以支援經營團隊決策。

對研究結果的全面回顧強調了協作證據、供應彈性和本地化訪問策略的必要性，以將臨床創新轉化為永續的患者結果。

現代減肥藥物市場環境的特徵是前所未有的治療潛力和複雜的可及性動態。科學創新提高了療效標準，並改變了人們對慢性病管理的期望，但可及性和可負擔性的考量，加上供應鏈和監管的複雜性，正在減緩這些治療方法轉化為人群層面影響的速度。因此，決策者必須整合臨床、營運和商業規劃，才能實現長期價值。

永續的成功將有利於那些積極主動地將證據產生與付款方期望相結合、建立具有韌性和靈活性的供應鏈、並設計以患者為中心的交付模式以減少依從性障礙的機構。區域差異性要求制定在地化策略，在尊重監管規範和付款方決策框架的同時，充分利用全球證據。總而言之，需要跨職能部門和相關人員的協作行動，將臨床進展轉化為有意義且公平的病患治療結果。

這一結論強調了及時、基於證據的策略執行的必要性。那些果斷採取行動，將臨床創新與切實可行的可及性解決方案相結合的公司，將在快速發展的治療領域中獲得先發優勢。

目錄

第1章：前言

第2章調查方法

第3章執行摘要

第4章 市場概況

第5章 市場洞察

  • 醫生處方中 GLP-1 受體促效劑聯合治療用於體重管理的趨勢不斷發展
  • 付款人實施分步編輯通訊協定以管理新型抗肥胖藥物不斷上漲的成本
  • 直接面對消費者的行銷宣傳活動推動了患者對注射減重治療的需求
  • 口服 GLP-1促效劑的出現徹底改變了肥胖治療中的患者依從性
  • GIP 和 GLP-1 雙重促效劑的 III 期試驗已證明具有顯著的減重和代謝益處。
  • 針對減肥藥取得和治療結果方面的種族和社會經濟差異的健康公平舉措
  • 整合肥胖指導和處方藥依從性監測的遠端醫療平台
  • 生技Start-Ups利用精準醫療開發以胜肽為基礎的減重治療方法

第6章：2025年美國關稅的累積影響

第7章：人工智慧的累積影響，2025年

第 8 章：按產品類型分類的抗肥胖藥物市場

  • GLP-1促效劑
  • 納曲酮安非他酮
  • 奧利司他
  • 芬特明/托吡酯
  • Sglt2抑制劑

第9章 抗肥胖藥物市場（按劑型）

  • 膠囊
  • 注射
    • 預填充筆
    • 管瓶
  • 藥片

第 10 章。按給藥途徑分類的抗肥胖藥物市場

  • 注射
    • 自動注射器
    • 預填充筆
    • 管瓶
  • 鼻腔
  • 口服

第 11 章。 抗肥胖藥物市場（按最終用戶）

  • 診所
  • 居家照護環境
  • 醫院

第 12 章：按地區分類的減重藥物市場

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第 13 章：按類別分類的抗肥胖藥物市場

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第 14 章。各國抗肥胖藥物市場

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第15章競爭格局

  • 2024年市佔率分析
  • 2024年FPNV定位矩陣
  • 競爭分析
    • Novo Nordisk A/S
    • Eli Lilly and Company
    • Pfizer Inc.
    • AstraZeneca PLC
    • Boehringer Ingelheim International GmbH
    • Amgen Inc.
    • Zealand Pharma A/S
    • Gelesis, Inc.
    • F. Hoffmann-La Roche AG
    • GlaxoSmithKline plc
Product Code: MRR-434CCDA05185

The Anti-Obesity Drugs Market is projected to grow by USD 7.07 billion at a CAGR of 7.06% by 2032.

KEY MARKET STATISTICS
Base Year [2024] USD 4.09 billion
Estimated Year [2025] USD 4.38 billion
Forecast Year [2032] USD 7.07 billion
CAGR (%) 7.06%

A strategic orientation to the modern anti-obesity therapy environment emphasizing clinical advances, stakeholder expectations, and operational imperatives for sustained program success

The therapeutic landscape for anti-obesity drugs has evolved from a niche clinical conversation into a mainstream strategic priority for biopharma, payers, and health systems. Novel incretin-based agents and combination therapies have reshaped clinical expectations for durable weight loss and metabolic benefit, prompting fresh interest across commercial, clinical, and regulatory stakeholders. This shift requires executives to reconcile rapid therapeutic innovation with real-world considerations such as long-term safety, adherence modalities, and cost-effectiveness.

Clinicians are increasingly viewing obesity as a chronic disease that demands sustained pharmacologic intervention alongside lifestyle modification. Payers are responding with conditional coverage frameworks that emphasize outcomes and value-based contracting. Simultaneously, manufacturing and distribution ecosystems are adapting to the unique requirements of injectable formulations and complex biologics. Taken together, these cross-cutting forces create both opportunity and complexity for organizations seeking to launch or scale anti-obesity therapeutics.

This introduction frames the rest of the executive summary by highlighting the intersection of innovation, access, and systems-level readiness. The following sections outline the transformative shifts in the therapeutic landscape, tariff-related supply chain implications, segmentation-driven commercial insights, regional dynamics, competitive positioning, actionable recommendations, methodological underpinnings, and concluding priorities for decision-makers. Each element is intended to inform strategic planning, identify operational risks, and prioritize high-impact interventions for near- and mid-term horizons.

How scientific breakthroughs, evolving reimbursement models, and new delivery modalities are jointly redefining competitive dynamics and care pathways in obesity therapeutics

The anti-obesity drug landscape is undergoing transformative shifts driven by simultaneous clinical breakthroughs and evolving payer paradigms. Breakthroughs in incretin biology and dual-agonist platforms have materially raised efficacy benchmarks, altering prescribing patterns and elevating expectations for sustained metabolic benefit beyond weight reduction alone. This scientific momentum has catalyzed a cascade of label expansions, off-label prescribing considerations, and intensified head-to-head competition, which in turn is reshaping life-cycle planning and commercial launch strategies.

Concurrently, reimbursement frameworks are adapting. Payer strategies now increasingly emphasize longitudinal outcomes, tiered access, and novel contracting models that tie reimbursement to performance metrics. Health systems are reorienting care pathways to integrate pharmacotherapy into multidisciplinary obesity management programs, which affects utilization patterns across ambulatory clinics, hospitals, and homecare settings. Additionally, the proliferation of injectable delivery formats has introduced new logistics and patient education imperatives that manufacturers must address to ensure adherence and real-world effectiveness.

Together, these shifts require companies to pivot from product-centric launches toward integrated ecosystem plays that align clinical evidence generation, patient support services, and dynamic pricing approaches. Strategic differentiation will be achieved by those who can demonstrate durable outcomes, operationalize scalable distribution models, and collaborate effectively with payers and providers to lower barriers to long-term access.

An analysis of how the 2025 U.S. tariff adjustments reverberated through procurement, manufacturing realignment, payer coverage, and access strategies across the obesity drug ecosystem

U.S. tariff adjustments in 2025 created a ripple effect across the anti-obesity therapeutic value chain, amplifying vulnerabilities in import-dependent components and altering cost calculus for finished products. Raw material sourcing for biologics and complex small molecules often crosses multiple borders; tariffs on intermediate goods increased landed costs and incentivized firms to reevaluate supplier footprints. In response, procurement teams accelerated supplier diversification and explored forward contracts to hedge input-price volatility.

Manufacturers also reassessed global manufacturing footprints and considered nearshoring options to reduce exposure to tariff-induced price swings. This strategic realignment carries nontrivial implications for capacity planning, technology transfer timelines, and regulatory submissions, since moving production or altering supplier lists requires time-consuming validation and potential inspections by health authorities. Those delays can defer launches and complicate inventory planning for high-demand injectables, which are sensitive to cold-chain integrity and lead times.

Payers and providers reacted to increased product costs by tightening formulary placement and intensifying utilization management. Coverage policies leaned more heavily on prior authorization criteria tied to comorbidity profiles and demonstrated response, while some health systems increased their emphasis on cost-mitigating alternatives such as nonpharmacologic interventions or legacy oral agents. At the same time, manufacturers with vertically integrated supply chains or domestic production capability enjoyed a relative advantage, securing continuity of supply and greater pricing flexibility. In sum, tariff-driven pressures reinforced the strategic value of supply chain resilience, regulatory agility, and proactive stakeholder engagement to preserve patient access and commercial momentum.

Detailed segmentation insights linking product modality, dosage form, administration route, and end-user settings to distinct clinical and commercial opportunities

Segmentation-based analysis reveals differentiated opportunities and constraints across therapeutic, dosage, administration, and end-user vectors that should shape portfolio and commercial strategies. Based on product type, GLP-1 agonists and dual-agonist modalities are driving clinician demand through high-efficacy outcomes, while established agents such as naltrexone-bupropion, orlistat, phentermine-topiramate, and SGLT2 inhibitors retain relevance for specific patient cohorts and comorbidity-driven prescribing. Differing mechanisms of action and safety profiles mean that treatment sequencing, combination strategies, and contraindication management will remain central to clinical messaging.

Dosage form considerations materially influence patient adoption and supply chain design. The market's injectable formats, which include prefilled pens and vials, demand robust cold-chain logistics and comprehensive patient education programs to optimize adherence. Capsules and tablets retain advantages in convenience and prescribing simplicity, which can be critical where cost or patient preference limits injectable uptake. Consequently, lifecycle management must account for both clinical differentiation and practical delivery constraints to maximize uptake across diverse settings.

Route of administration further stratifies commercial and clinical strategies. Injectable pathways, including autoinjectors, prefilled pens, and vials, require investment in nurse and pharmacist training, remote monitoring support, and device ergonomics to reduce administration barriers. Nasal and oral routes offer differentiated value propositions for rapid onset or convenience, which can expand reach among patients with injection hesitancy. Finally, end-user segmentation into clinics, homecare settings, and hospitals influences distribution choices, channel economics, and the design of patient support services. Clinics and hospital outpatient programs often serve as early adopters for higher-acuity cases, while homecare services are increasingly central to chronic therapy adherence and long-term retention.

Regional variations in clinical adoption, payer requirements, and regulatory complexity driving differentiated access strategies across the Americas, EMEA, and Asia-Pacific

Regional dynamics exhibit distinct clinical, regulatory, and commercial contours that require tailored strategies for market entry and scale-up. In the Americas, strong payer influence, large-scale clinical adoption, and high patient demand for efficacious therapies create a competitive environment where evidence of long-term outcomes and cost-effectiveness is paramount. Manufacturers that can align with value-based contracting and patient-support infrastructure will find traction in both specialty clinics and broader ambulatory networks.

Europe, Middle East & Africa presents a heterogeneous landscape characterized by variable regulatory pathways, divergent reimbursement philosophies, and differing levels of clinical infrastructure. National health systems and regional payers often require more rigorous health technology assessments and comparative-effectiveness data, which increases the importance of region-specific evidence generation and early HTA engagement. In markets where public coverage is constrained, private pay and clinic-based models may drive initial uptake, and partnerships with regional distributors can optimize access.

Asia-Pacific is defined by rapid adoption in urban centers, diverse regulatory timelines, and a mix of public and private payer structures. High population density and increasing prevalence of cardiometabolic comorbidities make the region strategically critical, but manufacturers must navigate price sensitivity, differential prescribing practices, and growing local competition. Across all regions, a coherent approach to regulatory harmonization, local clinical data generation, and tailored patient-support ecosystems will be necessary to translate clinical promise into sustainable access and outcomes.

Competitive dynamics and corporate strategies that determine long-term leadership in anti-obesity therapeutics through evidence generation, supply resilience, and integrated patient solutions

Competitive positioning in the anti-obesity therapeutics arena is being shaped by a mix of established pharmaceutical companies and innovative biotechnology entrants. Market leaders are leveraging deep clinical development capabilities to expand indications and generate head-to-head evidence, while newer entrants are focusing on differentiated mechanisms, device innovation, or integrated patient-support propositions. Strategic partnerships, co-development agreements, and acquisitions are common as firms seek to accelerate pipeline maturation and extend commercial reach.

Companies that integrate robust outcomes data with scalable patient services will gain a competitive edge in payer negotiations and provider adoption. Those with strong manufacturing footprints and supply chain redundancy demonstrate advantage in maintaining continuity of supply during demand fluctuations. In parallel, firms investing in device ergonomics, digital adherence tools, and multidisciplinary care models are better positioned to address real-world effectiveness and retention challenges.

Intellectual property strategies and lifecycle management plans will also determine long-term positioning, particularly as biosimilar and small-molecule competitors enter the mix. Proactive management of regulatory exclusivities, device patents, and formulation improvements can extend commercial viability. Ultimately, companies that align clinical differentiation with operational excellence and payer-centric evidence will lead in converting scientific promise into sustained patient access.

High-impact, implementable recommendations for manufacturers and stakeholders to secure access, strengthen supply chains, and maximize real-world therapeutic value

Industry leaders should prioritize a set of actionable interventions that connect clinical promise to durable commercial outcomes. First, invest in a phased evidence generation plan that pairs pivotal trial data with pragmatic real-world studies designed to demonstrate sustained metabolic and quality-of-life benefits. Early engagement with payers and HTA bodies to align endpoints and evidence packages can reduce downstream access friction.

Second, strengthen supply chain resilience by diversifying suppliers, accelerating qualification of alternate sites, and exploring nearshoring where appropriate to mitigate tariff and logistical risk. Parallel investments in cold-chain capacity and inventory management systems will be crucial for high-demand injectables. Third, design patient support models that address initiation and long-term adherence: build multichannel education for injection technique, leverage digital adherence tools, and coordinate with clinics and homecare providers to create continuity of care.

Fourth, adopt flexible commercial models that include outcomes-based contracting, tiered pricing, and indication-specific formulary strategies. Tailor messaging and patient journeys to administration route and dosage form preferences, and optimize device design to reduce friction. Finally, pursue strategic collaborations for distribution, telehealth integration, and local evidence generation to accelerate access across heterogeneous regional markets. Executing these actions in parallel will materially enhance the probability of sustained uptake and payer alignment.

A rigorous multi-method research framework combining stakeholder interviews, regulatory review, clinical evidence synthesis, and scenario analysis to drive strategic conclusions

The research underpinning this executive summary combined a multi-method approach to ensure balanced, actionable insights. Primary qualitative interviews were conducted with clinicians across endocrinology and bariatric medicine, hospital pharmacy directors, payer policy leads, and supply chain executives to surface near-term operational risks and adoption drivers. Regulatory and clinical guidance documents were systematically reviewed alongside public trial registries to validate therapeutic positioning, safety signals, and endpoints shaping coverage discussions.

Quantitative synthesis drew on prescription trends from public health data, clinical trial outcome reporting, and product approvals to map adoption trajectories and identify channel-centric demand signals. Scenario planning techniques were applied to evaluate tariff impacts, manufacturing reallocation timelines, and potential payer responses under varying cost and supply conditions. Finally, cross-functional workshops with commercial, medical affairs, and regulatory experts informed the development of pragmatic recommendations that balance clinical rigor with commercial reality.

Quality assurance measures included triangulation across multiple data sources, validation of key findings with subject-matter experts, and sensitivity analysis around supply chain assumptions. The resulting methodology prioritizes transparency, replicability, and strategic relevance to support executive decision-making.

Concluding synthesis underscoring the necessity of coordinated evidence, supply resilience, and localized access strategies to convert clinical innovation into sustained patient outcomes

The contemporary anti-obesity drug environment is defined by unprecedented therapeutic potential and complex access dynamics. Scientific innovation has raised the bar for efficacy and shifted expectations around chronic disease management, yet access and affordability considerations, coupled with supply chain and regulatory complexity, temper the pace at which those therapies translate to population-level impact. Decision-makers must therefore integrate clinical, operational, and commercial planning to realize long-term value.

Sustainable success will favor organizations that proactively align evidence generation with payer expectations, build resilient and flexible supply chains, and design patient-centric delivery models that reduce adherence barriers. Regional heterogeneity demands localized strategies that respect regulatory norms and payer decision-making frameworks while leveraging global evidence. Taken together, the path forward requires coordinated action across functions and stakeholders to convert clinical advances into meaningful, equitable patient outcomes.

This conclusion underscores the imperative for timely, evidence-informed strategy execution: firms that move decisively to reconcile clinical innovation with pragmatic access solutions will capture the first-mover advantages in a rapidly evolving therapeutic category.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Physician prescribing preferences evolving toward GLP-1 receptor agonist combination therapies for weight management
  • 5.2. Payers implementing step edit protocols to manage rising costs of novel anti-obesity medications
  • 5.3. Direct to consumer marketing campaigns driving patient demand for injectable obesity treatments
  • 5.4. Emergence of oral GLP-1 agonist formulations transforming patient adherence in obesity care
  • 5.5. Phase III trials of dual GIP and GLP-1 agonists demonstrating superior weight loss and metabolic benefits
  • 5.6. Health equity initiatives targeting racial and socioeconomic disparities in obesity drug access and outcomes
  • 5.7. Telehealth platforms integrating obesity coaching with prescription medication adherence monitoring
  • 5.8. Biotech startups leveraging precision medicine to develop peptide based therapies for targeted weight reduction

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Anti-Obesity Drugs Market, by Product Type

  • 8.1. Glp-1 Agonists
  • 8.2. Naltrexone Bupropion
  • 8.3. Orlistat
  • 8.4. Phentermine Topiramate
  • 8.5. Sglt2 Inhibitors

9. Anti-Obesity Drugs Market, by Dosage Form

  • 9.1. Capsules
  • 9.2. Injectables
    • 9.2.1. Prefilled Pens
    • 9.2.2. Vials
  • 9.3. Tablets

10. Anti-Obesity Drugs Market, by Route Of Administration

  • 10.1. Injectable
    • 10.1.1. Autoinjector
    • 10.1.2. Prefilled Pen
    • 10.1.3. Vial
  • 10.2. Nasal
  • 10.3. Oral

11. Anti-Obesity Drugs Market, by End User

  • 11.1. Clinics
  • 11.2. Homecare Settings
  • 11.3. Hospitals

12. Anti-Obesity Drugs Market, by Region

  • 12.1. Americas
    • 12.1.1. North America
    • 12.1.2. Latin America
  • 12.2. Europe, Middle East & Africa
    • 12.2.1. Europe
    • 12.2.2. Middle East
    • 12.2.3. Africa
  • 12.3. Asia-Pacific

13. Anti-Obesity Drugs Market, by Group

  • 13.1. ASEAN
  • 13.2. GCC
  • 13.3. European Union
  • 13.4. BRICS
  • 13.5. G7
  • 13.6. NATO

14. Anti-Obesity Drugs Market, by Country

  • 14.1. United States
  • 14.2. Canada
  • 14.3. Mexico
  • 14.4. Brazil
  • 14.5. United Kingdom
  • 14.6. Germany
  • 14.7. France
  • 14.8. Russia
  • 14.9. Italy
  • 14.10. Spain
  • 14.11. China
  • 14.12. India
  • 14.13. Japan
  • 14.14. Australia
  • 14.15. South Korea

15. Competitive Landscape

  • 15.1. Market Share Analysis, 2024
  • 15.2. FPNV Positioning Matrix, 2024
  • 15.3. Competitive Analysis
    • 15.3.1. Novo Nordisk A/S
    • 15.3.2. Eli Lilly and Company
    • 15.3.3. Pfizer Inc.
    • 15.3.4. AstraZeneca PLC
    • 15.3.5. Boehringer Ingelheim International GmbH
    • 15.3.6. Amgen Inc.
    • 15.3.7. Zealand Pharma A/S
    • 15.3.8. Gelesis, Inc.
    • 15.3.9. F. Hoffmann-La Roche AG
    • 15.3.10. GlaxoSmithKline plc

LIST OF FIGURES

  • FIGURE 1. GLOBAL ANTI-OBESITY DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL ANTI-OBESITY DRUGS MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2032 (%)
  • FIGURE 3. GLOBAL ANTI-OBESITY DRUGS MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 4. GLOBAL ANTI-OBESITY DRUGS MARKET SIZE, BY DOSAGE FORM, 2024 VS 2032 (%)
  • FIGURE 5. GLOBAL ANTI-OBESITY DRUGS MARKET SIZE, BY DOSAGE FORM, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL ANTI-OBESITY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2032 (%)
  • FIGURE 7. GLOBAL ANTI-OBESITY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL ANTI-OBESITY DRUGS MARKET SIZE, BY END USER, 2024 VS 2032 (%)
  • FIGURE 9. GLOBAL ANTI-OBESITY DRUGS MARKET SIZE, BY END USER, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL ANTI-OBESITY DRUGS MARKET SIZE, BY REGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 11. AMERICAS ANTI-OBESITY DRUGS MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 12. NORTH AMERICA ANTI-OBESITY DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 13. LATIN AMERICA ANTI-OBESITY DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 14. EUROPE, MIDDLE EAST & AFRICA ANTI-OBESITY DRUGS MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 15. EUROPE ANTI-OBESITY DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 16. MIDDLE EAST ANTI-OBESITY DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 17. AFRICA ANTI-OBESITY DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 18. ASIA-PACIFIC ANTI-OBESITY DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 19. GLOBAL ANTI-OBESITY DRUGS MARKET SIZE, BY GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 20. ASEAN ANTI-OBESITY DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 21. GCC ANTI-OBESITY DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 22. EUROPEAN UNION ANTI-OBESITY DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 23. BRICS ANTI-OBESITY DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 24. G7 ANTI-OBESITY DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 25. NATO ANTI-OBESITY DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 26. GLOBAL ANTI-OBESITY DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 27. ANTI-OBESITY DRUGS MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 28. ANTI-OBESITY DRUGS MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

  • TABLE 1. ANTI-OBESITY DRUGS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
  • TABLE 3. GLOBAL ANTI-OBESITY DRUGS MARKET SIZE, 2018-2024 (USD MILLION)
  • TABLE 4. GLOBAL ANTI-OBESITY DRUGS MARKET SIZE, 2025-2032 (USD MILLION)
  • TABLE 5. GLOBAL ANTI-OBESITY DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 6. GLOBAL ANTI-OBESITY DRUGS MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 7. GLOBAL ANTI-OBESITY DRUGS MARKET SIZE, BY GLP-1 AGONISTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 8. GLOBAL ANTI-OBESITY DRUGS MARKET SIZE, BY GLP-1 AGONISTS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 9. GLOBAL ANTI-OBESITY DRUGS MARKET SIZE, BY GLP-1 AGONISTS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 10. GLOBAL ANTI-OBESITY DRUGS MARKET SIZE, BY GLP-1 AGONISTS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 11. GLOBAL ANTI-OBESITY DRUGS MARKET SIZE, BY GLP-1 AGONISTS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 12. GLOBAL ANTI-OBESITY DRUGS MARKET SIZE, BY GLP-1 AGONISTS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 13. GLOBAL ANTI-OBESITY DRUGS MARKET SIZE, BY NALTREXONE BUPROPION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 14. GLOBAL ANTI-OBESITY DRUGS MARKET SIZE, BY NALTREXONE BUPROPION, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 15. GLOBAL ANTI-OBESITY DRUGS MARKET SIZE, BY NALTREXONE BUPROPION, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 16. GLOBAL ANTI-OBESITY DRUGS MARKET SIZE, BY NALTREXONE BUPROPION, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 17. GLOBAL ANTI-OBESITY DRUGS MARKET SIZE, BY NALTREXONE BUPROPION, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 18. GLOBAL ANTI-OBESITY DRUGS MARKET SIZE, BY NALTREXONE BUPROPION, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 19. GLOBAL ANTI-OBESITY DRUGS MARKET SIZE, BY ORLISTAT, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 20. GLOBAL ANTI-OBESITY DRUGS MARKET SIZE, BY ORLISTAT, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 21. GLOBAL ANTI-OBESITY DRUGS MARKET SIZE, BY ORLISTAT, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 22. GLOBAL ANTI-OBESITY DRUGS MARKET SIZE, BY ORLISTAT, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 23. GLOBAL ANTI-OBESITY DRUGS MARKET SIZE, BY ORLISTAT, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 24. GLOBAL ANTI-OBESITY DRUGS MARKET SIZE, BY ORLISTAT, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 25. GLOBAL ANTI-OBESITY DRUGS MARKET SIZE, BY PHENTERMINE TOPIRAMATE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 26. GLOBAL ANTI-OBESITY DRUGS MARKET SIZE, BY PHENTERMINE TOPIRAMATE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 27. GLOBAL ANTI-OBESITY DRUGS MARKET SIZE, BY PHENTERMINE TOPIRAMATE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 28. GLOBAL ANTI-OBESITY DRUGS MARKET SIZE, BY PHENTERMINE TOPIRAMATE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 29. GLOBAL ANTI-OBESITY DRUGS MARKET SIZE, BY PHENTERMINE TOPIRAMATE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 30. GLOBAL ANTI-OBESITY DRUGS MARKET SIZE, BY PHENTERMINE TOPIRAMATE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 31. GLOBAL ANTI-OBESITY DRUGS MARKET SIZE, BY SGLT2 INHIBITORS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 32. GLOBAL ANTI-OBESITY DRUGS MARKET SIZE, BY SGLT2 INHIBITORS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 33. GLOBAL ANTI-OBESITY DRUGS MARKET SIZE, BY SGLT2 INHIBITORS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 34. GLOBAL ANTI-OBESITY DRUGS MARKET SIZE, BY SGLT2 INHIBITORS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 35. GLOBAL ANTI-OBESITY DRUGS MARKET SIZE, BY SGLT2 INHIBITORS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 36. GLOBAL ANTI-OBESITY DRUGS MARKET SIZE, BY SGLT2 INHIBITORS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 37. GLOBAL ANTI-OBESITY DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
  • TABLE 38. GLOBAL ANTI-OBESITY DRUGS MARKET SIZE, BY DOSAGE FORM, 2025-2032 (USD MILLION)
  • TABLE 39. GLOBAL ANTI-OBESITY DRUGS MARKET SIZE, BY CAPSULES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 40. GLOBAL ANTI-OBESITY DRUGS MARKET SIZE, BY CAPSULES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 41. GLOBAL ANTI-OBESITY DRUGS MARKET SIZE, BY CAPSULES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 42. GLOBAL ANTI-OBESITY DRUGS MARKET SIZE, BY CAPSULES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 43. GLOBAL ANTI-OBESITY DRUGS MARKET SIZE, BY CAPSULES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 44. GLOBAL ANTI-OBESITY DRUGS MARKET SIZE, BY CAPSULES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 45. GLOBAL ANTI-OBESITY DRUGS MARKET SIZE, BY INJECTABLES, 2018-2024 (USD MILLION)
  • TABLE 46. GLOBAL ANTI-OBESITY DRUGS MARKET SIZE, BY INJECTABLES, 2025-2032 (USD MILLION)
  • TABLE 47. GLOBAL ANTI-OBESITY DRUGS MARKET SIZE, BY INJECTABLES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 48. GLOBAL ANTI-OBESITY DRUGS MARKET SIZE, BY INJECTABLES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 49. GLOBAL ANTI-OBESITY DRUGS MARKET SIZE, BY INJECTABLES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 50. GLOBAL ANTI-OBESITY DRUGS MARKET SIZE, BY INJECTABLES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 51. GLOBAL ANTI-OBESITY DRUGS MARKET SIZE, BY INJECTABLES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 52. GLOBAL ANTI-OBESITY DRUGS MARKET SIZE, BY INJECTABLES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 53. GLOBAL ANTI-OBESITY DRUGS MARKET SIZE, BY PREFILLED PENS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 54. GLOBAL ANTI-OBESITY DRUGS MARKET SIZE, BY PREFILLED PENS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 55. GLOBAL ANTI-OBESITY DRUGS MARKET SIZE, BY PREFILLED PENS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 56. GLOBAL ANTI-OBESITY DRUGS MARKET SIZE, BY PREFILLED PENS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 57. GLOBAL ANTI-OBESITY DRUGS MARKET SIZE, BY PREFILLED PENS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 58. GLOBAL ANTI-OBESITY DRUGS MARKET SIZE, BY PREFILLED PENS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 59. GLOBAL ANTI-OBESITY DRUGS MARKET SIZE, BY VIALS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 60. GLOBAL ANTI-OBESITY DRUGS MARKET SIZE, BY VIALS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 61. GLOBAL ANTI-OBESITY DRUGS MARKET SIZE, BY VIALS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 62. GLOBAL ANTI-OBESITY DRUGS MARKET SIZE, BY VIALS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 63. GLOBAL ANTI-OBESITY DRUGS MARKET SIZE, BY VIALS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 64. GLOBAL ANTI-OBESITY DRUGS MARKET SIZE, BY VIALS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 65. GLOBAL ANTI-OBESITY DRUGS MARKET SIZE, BY TABLETS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 66. GLOBAL ANTI-OBESITY DRUGS MARKET SIZE, BY TABLETS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 67. GLOBAL ANTI-OBESITY DRUGS MARKET SIZE, BY TABLETS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 68. GLOBAL ANTI-OBESITY DRUGS MARKET SIZE, BY TABLETS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 69. GLOBAL ANTI-OBESITY DRUGS MARKET SIZE, BY TABLETS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 70. GLOBAL ANTI-OBESITY DRUGS MARKET SIZE, BY TABLETS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 71. GLOBAL ANTI-OBESITY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 72. GLOBAL ANTI-OBESITY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 73. GLOBAL ANTI-OBESITY DRUGS MARKET SIZE, BY INJECTABLE, 2018-2024 (USD MILLION)
  • TABLE 74. GLOBAL ANTI-OBESITY DRUGS MARKET SIZE, BY INJECTABLE, 2025-2032 (USD MILLION)
  • TABLE 75. GLOBAL ANTI-OBESITY DRUGS MARKET SIZE, BY INJECTABLE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 76. GLOBAL ANTI-OBESITY DRUGS MARKET SIZE, BY INJECTABLE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 77. GLOBAL ANTI-OBESITY DRUGS MARKET SIZE, BY INJECTABLE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 78. GLOBAL ANTI-OBESITY DRUGS MARKET SIZE, BY INJECTABLE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 79. GLOBAL ANTI-OBESITY DRUGS MARKET SIZE, BY INJECTABLE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 80. GLOBAL ANTI-OBESITY DRUGS MARKET SIZE, BY INJECTABLE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 81. GLOBAL ANTI-OBESITY DRUGS MARKET SIZE, BY AUTOINJECTOR, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 82. GLOBAL ANTI-OBESITY DRUGS MARKET SIZE, BY AUTOINJECTOR, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 83. GLOBAL ANTI-OBESITY DRUGS MARKET SIZE, BY AUTOINJECTOR, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 84. GLOBAL ANTI-OBESITY DRUGS MARKET SIZE, BY AUTOINJECTOR, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 85. GLOBAL ANTI-OBESITY DRUGS MARKET SIZE, BY AUTOINJECTOR, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 86. GLOBAL ANTI-OBESITY DRUGS MARKET SIZE, BY AUTOINJECTOR, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 87. GLOBAL ANTI-OBESITY DRUGS MARKET SIZE, BY PREFILLED PEN, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 88. GLOBAL ANTI-OBESITY DRUGS MARKET SIZE, BY PREFILLED PEN, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 89. GLOBAL ANTI-OBESITY DRUGS MARKET SIZE, BY PREFILLED PEN, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 90. GLOBAL ANTI-OBESITY DRUGS MARKET SIZE, BY PREFILLED PEN, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 91. GLOBAL ANTI-OBESITY DRUGS MARKET SIZE, BY PREFILLED PEN, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 92. GLOBAL ANTI-OBESITY DRUGS MARKET SIZE, BY PREFILLED PEN, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 93. GLOBAL ANTI-OBESITY DRUGS MARKET SIZE, BY VIAL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 94. GLOBAL ANTI-OBESITY DRUGS MARKET SIZE, BY VIAL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 95. GLOBAL ANTI-OBESITY DRUGS MARKET SIZE, BY VIAL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 96. GLOBAL ANTI-OBESITY DRUGS MARKET SIZE, BY VIAL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 97. GLOBAL ANTI-OBESITY DRUGS MARKET SIZE, BY VIAL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 98. GLOBAL ANTI-OBESITY DRUGS MARKET SIZE, BY VIAL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 99. GLOBAL ANTI-OBESITY DRUGS MARKET SIZE, BY NASAL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 100. GLOBAL ANTI-OBESITY DRUGS MARKET SIZE, BY NASAL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 101. GLOBAL ANTI-OBESITY DRUGS MARKET SIZE, BY NASAL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 102. GLOBAL ANTI-OBESITY DRUGS MARKET SIZE, BY NASAL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 103. GLOBAL ANTI-OBESITY DRUGS MARKET SIZE, BY NASAL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 104. GLOBAL ANTI-OBESITY DRUGS MARKET SIZE, BY NASAL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 105. GLOBAL ANTI-OBESITY DRUGS MARKET SIZE, BY ORAL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 106. GLOBAL ANTI-OBESITY DRUGS MARKET SIZE, BY ORAL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 107. GLOBAL ANTI-OBESITY DRUGS MARKET SIZE, BY ORAL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 108. GLOBAL ANTI-OBESITY DRUGS MARKET SIZE, BY ORAL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 109. GLOBAL ANTI-OBESITY DRUGS MARKET SIZE, BY ORAL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 110. GLOBAL ANTI-OBESITY DRUGS MARKET SIZE, BY ORAL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 111. GLOBAL ANTI-OBESITY DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 112. GLOBAL ANTI-OBESITY DRUGS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 113. GLOBAL ANTI-OBESITY DRUGS MARKET SIZE, BY CLINICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 114. GLOBAL ANTI-OBESITY DRUGS MARKET SIZE, BY CLINICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 115. GLOBAL ANTI-OBESITY DRUGS MARKET SIZE, BY CLINICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 116. GLOBAL ANTI-OBESITY DRUGS MARKET SIZE, BY CLINICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 117. GLOBAL ANTI-OBESITY DRUGS MARKET SIZE, BY CLINICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 118. GLOBAL ANTI-OBESITY DRUGS MARKET SIZE, BY CLINICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 119. GLOBAL ANTI-OBESITY DRUGS MARKET SIZE, BY HOMECARE SETTINGS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 120. GLOBAL ANTI-OBESITY DRUGS MARKET SIZE, BY HOMECARE SETTINGS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 121. GLOBAL ANTI-OBESITY DRUGS MARKET SIZE, BY HOMECARE SETTINGS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 122. GLOBAL ANTI-OBESITY DRUGS MARKET SIZE, BY HOMECARE SETTINGS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 123. GLOBAL ANTI-OBESITY DRUGS MARKET SIZE, BY HOMECARE SETTINGS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 124. GLOBAL ANTI-OBESITY DRUGS MARKET SIZE, BY HOMECARE SETTINGS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 125. GLOBAL ANTI-OBESITY DRUGS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 126. GLOBAL ANTI-OBESITY DRUGS MARKET SIZE, BY HOSPITALS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 127. GLOBAL ANTI-OBESITY DRUGS MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 128. GLOBAL ANTI-OBESITY DRUGS MARKET SIZE, BY HOSPITALS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 129. GLOBAL ANTI-OBESITY DRUGS MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 130. GLOBAL ANTI-OBESITY DRUGS MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 131. GLOBAL ANTI-OBESITY DRUGS MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 132. GLOBAL ANTI-OBESITY DRUGS MARKET SIZE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 133. AMERICAS ANTI-OBESITY DRUGS MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 134. AMERICAS ANTI-OBESITY DRUGS MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 135. AMERICAS ANTI-OBESITY DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 136. AMERICAS ANTI-OBESITY DRUGS MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 137. AMERICAS ANTI-OBESITY DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
  • TABLE 138. AMERICAS ANTI-OBESITY DRUGS MARKET SIZE, BY DOSAGE FORM, 2025-2032 (USD MILLION)
  • TABLE 139. AMERICAS ANTI-OBESITY DRUGS MARKET SIZE, BY INJECTABLES, 2018-2024 (USD MILLION)
  • TABLE 140. AMERICAS ANTI-OBESITY DRUGS MARKET SIZE, BY INJECTABLES, 2025-2032 (USD MILLION)
  • TABLE 141. AMERICAS ANTI-OBESITY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 142. AMERICAS ANTI-OBESITY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 143. AMERICAS ANTI-OBESITY DRUGS MARKET SIZE, BY INJECTABLE, 2018-2024 (USD MILLION)
  • TABLE 144. AMERICAS ANTI-OBESITY DRUGS MARKET SIZE, BY INJECTABLE, 2025-2032 (USD MILLION)
  • TABLE 145. AMERICAS ANTI-OBESITY DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 146. AMERICAS ANTI-OBESITY DRUGS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 147. NORTH AMERICA ANTI-OBESITY DRUGS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 148. NORTH AMERICA ANTI-OBESITY DRUGS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 149. NORTH AMERICA ANTI-OBESITY DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 150. NORTH AMERICA ANTI-OBESITY DRUGS MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 151. NORTH AMERICA ANTI-OBESITY DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
  • TABLE 152. NORTH AMERICA ANTI-OBESITY DRUGS MARKET SIZE, BY DOSAGE FORM, 2025-2032 (USD MILLION)
  • TABLE 153. NORTH AMERICA ANTI-OBESITY DRUGS MARKET SIZE, BY INJECTABLES, 2018-2024 (USD MILLION)
  • TABLE 154. NORTH AMERICA ANTI-OBESITY DRUGS MARKET SIZE, BY INJECTABLES, 2025-2032 (USD MILLION)
  • TABLE 155. NORTH AMERICA ANTI-OBESITY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 156. NORTH AMERICA ANTI-OBESITY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 157. NORTH AMERICA ANTI-OBESITY DRUGS MARKET SIZE, BY INJECTABLE, 2018-2024 (USD MILLION)
  • TABLE 158. NORTH AMERICA ANTI-OBESITY DRUGS MARKET SIZE, BY INJECTABLE, 2025-2032 (USD MILLION)
  • TABLE 159. NORTH AMERICA ANTI-OBESITY DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 160. NORTH AMERICA ANTI-OBESITY DRUGS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 161. LATIN AMERICA ANTI-OBESITY DRUGS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 162. LATIN AMERICA ANTI-OBESITY DRUGS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 163. LATIN AMERICA ANTI-OBESITY DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 164. LATIN AMERICA ANTI-OBESITY DRUGS MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 165. LATIN AMERICA ANTI-OBESITY DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
  • TABLE 166. LATIN AMERICA ANTI-OBESITY DRUGS MARKET SIZE, BY DOSAGE FORM, 2025-2032 (USD MILLION)
  • TABLE 167. LATIN AMERICA ANTI-OBESITY DRUGS MARKET SIZE, BY INJECTABLES, 2018-2024 (USD MILLION)
  • TABLE 168. LATIN AMERICA ANTI-OBESITY DRUGS MARKET SIZE, BY INJECTABLES, 2025-2032 (USD MILLION)
  • TABLE 169. LATIN AMERICA ANTI-OBESITY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 170. LATIN AMERICA ANTI-OBESITY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 171. LATIN AMERICA ANTI-OBESITY DRUGS MARKET SIZE, BY INJECTABLE, 2018-2024 (USD MILLION)
  • TABLE 172. LATIN AMERICA ANTI-OBESITY DRUGS MARKET SIZE, BY INJECTABLE, 2025-2032 (USD MILLION)
  • TABLE 173. LATIN AMERICA ANTI-OBESITY DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 174. LATIN AMERICA ANTI-OBESITY DRUGS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 175. EUROPE, MIDDLE EAST & AFRICA ANTI-OBESITY DRUGS MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 176. EUROPE, MIDDLE EAST & AFRICA ANTI-OBESITY DRUGS MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 177. EUROPE, MIDDLE EAST & AFRICA ANTI-OBESITY DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 178. EUROPE, MIDDLE EAST & AFRICA ANTI-OBESITY DRUGS MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 179. EUROPE, MIDDLE EAST & AFRICA ANTI-OBESITY DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
  • TABLE 180. EUROPE, MIDDLE EAST & AFRICA ANTI-OBESITY DRUGS MARKET SIZE, BY DOSAGE FORM, 2025-2032 (USD MILLION)
  • TABLE 181. EUROPE, MIDDLE EAST & AFRICA ANTI-OBESITY DRUGS MARKET SIZE, BY INJECTABLES, 2018-2024 (USD MILLION)
  • TABLE 182. EUROPE, MIDDLE EAST & AFRICA ANTI-OBESITY DRUGS MARKET SIZE, BY INJECTABLES, 2025-2032 (USD MILLION)
  • TABLE 183. EUROPE, MIDDLE EAST & AFRICA ANTI-OBESITY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 184. EUROPE, MIDDLE EAST & AFRICA ANTI-OBESITY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 185. EUROPE, MIDDLE EAST & AFRICA ANTI-OBESITY DRUGS MARKET SIZE, BY INJECTABLE, 2018-2024 (USD MILLION)
  • TABLE 186. EUROPE, MIDDLE EAST & AFRICA ANTI-OBESITY DRUGS MARKET SIZE, BY INJECTABLE, 2025-2032 (USD MILLION)
  • TABLE 187. EUROPE, MIDDLE EAST & AFRICA ANTI-OBESITY DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 188. EUROPE, MIDDLE EAST & AFRICA ANTI-OBESITY DRUGS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 189. EUROPE ANTI-OBESITY DRUGS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 190. EUROPE ANTI-OBESITY DRUGS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 191. EUROPE ANTI-OBESITY DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 192. EUROPE ANTI-OBESITY DRUGS MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 193. EUROPE ANTI-OBESITY DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
  • TABLE 194. EUROPE ANTI-OBESITY DRUGS MARKET SIZE, BY DOSAGE FORM, 2025-2032 (USD MILLION)
  • TABLE 195. EUROPE ANTI-OBESITY DRUGS MARKET SIZE, BY INJECTABLES, 2018-2024 (USD MILLION)
  • TABLE 196. EUROPE ANTI-OBESITY DRUGS MARKET SIZE, BY INJECTABLES, 2025-2032 (USD MILLION)
  • TABLE 197. EUROPE ANTI-OBESITY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 198. EUROPE ANTI-OBESITY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 199. EUROPE ANTI-OBESITY DRUGS MARKET SIZE, BY INJECTABLE, 2018-2024 (USD MILLION)
  • TABLE 200. EUROPE ANTI-OBESITY DRUGS MARKET SIZE, BY INJECTABLE, 2025-2032 (USD MILLION)
  • TABLE 201. EUROPE ANTI-OBESITY DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 202. EUROPE ANTI-OBESITY DRUGS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 203. MIDDLE EAST ANTI-OBESITY DRUGS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 204. MIDDLE EAST ANTI-OBESITY DRUGS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 205. MIDDLE EAST ANTI-OBESITY DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 206. MIDDLE EAST ANTI-OBESITY DRUGS MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 207. MIDDLE EAST ANTI-OBESITY DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
  • TABLE 208. MIDDLE EAST ANTI-OBESITY DRUGS MARKET SIZE, BY DOSAGE FORM, 2025-2032 (USD MILLION)
  • TABLE 209. MIDDLE EAST ANTI-OBESITY DRUGS MARKET SIZE, BY INJECTABLES, 2018-2024 (USD MILLION)
  • TABLE 210. MIDDLE EAST ANTI-OBESITY DRUGS MARKET SIZE, BY INJECTABLES, 2025-2032 (USD MILLION)
  • TABLE 211. MIDDLE EAST ANTI-OBESITY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 212. MIDDLE EAST ANTI-OBESITY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 213. MIDDLE EAST ANTI-OBESITY DRUGS MARKET SIZE, BY INJECTABLE, 2018-2024 (USD MILLION)
  • TABLE 214. MIDDLE EAST ANTI-OBESITY DRUGS MARKET SIZE, BY INJECTABLE, 2025-2032 (USD MILLION)
  • TABLE 215. MIDDLE EAST ANTI-OBESITY DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 216. MIDDLE EAST ANTI-OBESITY DRUGS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 217. AFRICA ANTI-OBESITY DRUGS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 218. AFRICA ANTI-OBESITY DRUGS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 219. AFRICA ANTI-OBESITY DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 220. AFRICA ANTI-OBESITY DRUGS MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 221. AFRICA ANTI-OBESITY DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
  • TABLE 222. AFRICA ANTI-OBESITY DRUGS MARKET SIZE, BY DOSAGE FORM, 2025-2032 (USD MILLION)
  • TABLE 223. AFRICA ANTI-OBESITY DRUGS MARKET SIZE, BY INJECTABLES, 2018-2024 (USD MILLION)
  • TABLE 224. AFRICA ANTI-OBESITY DRUGS MARKET SIZE, BY INJECTABLES, 2025-2032 (USD MILLION)
  • TABLE 225. AFRICA ANTI-OBESITY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 226. AFRICA ANTI-OBESITY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 227. AFRICA ANTI-OBESITY DRUGS MARKET SIZE, BY INJECTABLE, 2018-2024 (USD MILLION)
  • TABLE 228. AFRICA ANTI-OBESITY DRUGS MARKET SIZE, BY INJECTABLE, 2025-2032 (USD MILLION)
  • TABLE 229. AFRICA ANTI-OBESITY DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 230. AFRICA ANTI-OBESITY DRUGS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 231. ASIA-PACIFIC ANTI-OBESITY DRUGS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 232. ASIA-PACIFIC ANTI-OBESITY DRUGS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 233. ASIA-PACIFIC ANTI-OBESITY DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 234. ASIA-PACIFIC ANTI-OBESITY DRUGS MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 235. ASIA-PACIFIC ANTI-OBESITY DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
  • TABLE 236. ASIA-PACIFIC ANTI-OBESITY DRUGS MARKET SIZE, BY DOSAGE FORM, 2025-2032 (USD MILLION)
  • TABLE 237. ASIA-PACIFIC ANTI-OBESITY DRUGS MARKET SIZE, BY INJECTABLES, 2018-2024 (USD MILLION)
  • TABLE 238. ASIA-PACIFIC ANTI-OBESITY DRUGS MARKET SIZE, BY INJECTABLES, 2025-2032 (USD MILLION)
  • TABLE 239. ASIA-PACIFIC ANTI-OBESITY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 240. ASIA-PACIFIC ANTI-OBESITY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 241. ASIA-PACIFIC ANTI-OBESITY DRUGS MARKET SIZE, BY INJECTABLE, 2018-2024 (USD MILLION)
  • TABLE 242. ASIA-PACIFIC ANTI-OBESITY DRUGS MARKET SIZE, BY INJECTABLE, 2025-2032 (USD MILLION)
  • TABLE 243. ASIA-PACIFIC ANTI-OBESITY DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 244. ASIA-PACIFIC ANTI-OBESITY DRUGS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 245. GLOBAL ANTI-OBESITY DRUGS MARKET SIZE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 246. GLOBAL ANTI-OBESITY DRUGS MARKET SIZE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 247. ASEAN ANTI-OBESITY DRUGS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 248. ASEAN ANTI-OBESITY DRUGS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 249. ASEAN ANTI-OBESITY DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 250. ASEAN ANTI-OBESITY DRUGS MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 251. ASEAN ANTI-OBESITY DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
  • TABLE 252. ASEAN ANTI-OBESITY DRUGS MARKET SIZE, BY DOSAGE FORM, 2025-2032 (USD MILLION)
  • TABLE 253. ASEAN ANTI-OBESITY DRUGS MARKET SIZE, BY INJECTABLES, 2018-2024 (USD MILLION)
  • TABLE 254. ASEAN ANTI-OBESITY DRUGS MARKET SIZE, BY INJECTABLES, 2025-2032 (USD MILLION)
  • TABLE 255. ASEAN ANTI-OBESITY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 256. ASEAN ANTI-OBESITY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 257. ASEAN ANTI-OBESITY DRUGS MARKET SIZE, BY INJECTABLE, 2018-2024 (USD MILLION)
  • TABLE 258. ASEAN ANTI-OBESITY DRUGS MARKET SIZE, BY INJECTABLE, 2025-2032 (USD MILLION)
  • TABLE 259. ASEAN ANTI-OBESITY DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 260. ASEAN ANTI-OBESITY DRUGS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 261. GCC ANTI-OBESITY DRUGS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 262. GCC ANTI-OBESITY DRUGS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 263. GCC ANTI-OBESITY DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 264. GCC ANTI-OBESITY DRUGS MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 265. GCC ANTI-OBESITY DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
  • TABLE 266. GCC ANTI-OBESITY DRUGS MARKET SIZE, BY DOSAGE FORM, 2025-2032 (USD MILLION)
  • TABLE 267. GCC ANTI-OBESITY DRUGS MARKET SIZE, BY INJECTABLES, 2018-2024 (USD MILLION)
  • TABLE 268. GCC ANTI-OBESITY DRUGS MARKET SIZE, BY INJECTABLES, 2025-2032 (USD MILLION)
  • TABLE 269. GCC ANTI-OBESITY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 270. GCC ANTI-OBESITY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 271. GCC ANTI-OBESITY DRUGS MARKET SIZE, BY INJECTABLE, 2018-2024 (USD MILLION)
  • TABLE 272. GCC ANTI-OBESITY DRUGS MARKET SIZE, BY INJECTABLE, 2025-2032 (USD MILLION)
  • TABLE 273. GCC ANTI-OBESITY DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 274. GCC ANTI-OBESITY DRUGS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 275. EUROPEAN UNION ANTI-OBESITY DRUGS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 276. EUROPEAN UNION ANTI-OBESITY DRUGS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 277. EUROPEAN UNION ANTI-OBESITY DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 278. EUROPEAN UNION ANTI-OBESITY DRUGS MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 279. EUROPEAN UNION ANTI-OBESITY DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
  • TABLE 280. EUROPEAN UNION ANTI-OBESITY DRUGS MARKET SIZE, BY DOSAGE FORM, 2025-2032 (USD MILLION)
  • TABLE 281. EUROPEAN UNION ANTI-OBESITY DRUGS MARKET SIZE, BY INJECTABLES, 2018-2024 (USD MILLION)
  • TABLE 282. EUROPEAN UNION ANTI-OBESITY DRUGS MARKET SIZE, BY INJECTABLES, 2025-2032 (USD MILLION)
  • TABLE 283. EUROPEAN UNION ANTI-OBESITY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 284. EUROPEAN UNION ANTI-OBESITY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 285. EUROPEAN UNION ANTI-OBESITY DRUGS MARKET SIZE, BY INJECTABLE, 2018-2024 (USD MILLION)
  • TABLE 286. EUROPEAN UNION ANTI-OBESITY DRUGS MARKET SIZE, BY INJECTABLE, 2025-2032 (USD MILLION)
  • TABLE 287. EUROPEAN UNION ANTI-OBESITY DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 288. EUROPEAN UNION ANTI-OBESITY DRUGS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 289. BRICS ANTI-OBESITY DRUGS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 290. BRICS ANTI-OBESITY DRUGS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 291. BRICS ANTI-OBESITY DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 292. BRICS ANTI-OBESITY DRUGS MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 293. BRICS ANTI-OBESITY DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
  • TABLE 294. BRICS ANTI-OBESITY DRUGS MARKET SIZE, BY DOSAGE FORM, 2025-2032 (USD MILLION)
  • TABLE 295. BRICS ANTI-OBESITY DRUGS MARKET SIZE, BY INJECTABLES, 2018-2024 (USD MILLION)
  • TABLE 296. BRICS ANTI-OBESITY DRUGS MARKET SIZE, BY INJECTABLES, 2025-2032 (USD MILLION)
  • TABLE 297. BRICS ANTI-OBESITY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 298. BRICS ANTI-OBESITY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 299. BRICS ANTI-OBESITY DRUGS MARKET SIZE, BY INJECTABLE, 2018-2024 (USD MILLION)
  • TABLE 300. BRICS ANTI-OBESITY DRUGS MARKET SIZE, BY INJECTABLE, 2025-2032 (USD MILLION)
  • TABLE 301. BRICS ANTI-OBESITY DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 302. BRICS ANTI-OBESITY DRUGS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 303. G7 ANTI-OBESITY DRUGS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 304. G7 ANTI-OBESITY DRUGS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 305. G7 ANTI-OBESITY DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 306. G7 ANTI-OBESITY DRUGS MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 307. G7 ANTI-OBESITY DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
  • TABLE 308. G7 ANTI-OBESITY DRUGS MARKET SIZE, BY DOSAGE FORM, 2025-2032 (USD MILLION)
  • TABLE 309. G7 ANTI-OBESITY DRUGS MARKET SIZE, BY INJECTABLES, 2018-2024 (USD MILLION)
  • TABLE 310. G7 ANTI-OBESITY DRUGS MARKET SIZE, BY INJECTABLES, 2025-2032 (USD MILLION)
  • TABLE 311. G7 ANTI-OBESITY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 312. G7 ANTI-OBESITY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 313. G7 ANTI-OBESITY DRUGS MARKET SIZE, BY INJECTABLE, 2018-2024 (USD MILLION)
  • TABLE 314. G7 ANTI-OBESITY DRUGS MARKET SIZE, BY INJECTABLE, 2025-2032 (USD MILLION)
  • TABLE 315. G7 ANTI-OBESITY DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 316. G7 ANTI-OBESITY DRUGS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 317. NATO ANTI-OBESITY DRUGS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 318. NATO ANTI-OBESITY DRUGS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 319. NATO ANTI-OBESITY DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 320. NATO ANTI-OBESITY DRUGS MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 321. NATO ANTI-OBESITY DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
  • TABLE 322. NATO ANTI-OBESITY DRUGS MARKET SIZE, BY DOSAGE FORM, 2025-2032 (USD MILLION)
  • TABLE 323. NATO ANTI-OBESITY DRUGS MARKET SIZE, BY INJECTABLES, 2018-2024 (USD MILLION)
  • TABLE 324. NATO ANTI-OBESITY DRUGS MARKET SIZE, BY INJECTABLES, 2025-2032 (USD MILLION)
  • TABLE 325. NATO ANTI-OBESITY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 326. NATO ANTI-OBESITY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 327. NATO ANTI-OBESITY DRUGS MARKET SIZE, BY INJECTABLE, 2018-2024 (USD MILLION)
  • TABLE 328. NATO ANTI-OBESITY DRUGS MARKET SIZE, BY INJECTABLE, 2025-2032 (USD MILLION)
  • TABLE 329. NATO ANTI-OBESITY DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 330. NATO ANTI-OBESITY DRUGS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 331. GLOBAL ANTI-OBESITY DRUGS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 332. GLOBAL ANTI-OBESITY DRUGS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 333. UNITED STATES ANTI-OBESITY DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 334. UNITED STATES ANTI-OBESITY DRUGS MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 335. UNITED STATES ANTI-OBESITY DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
  • TABLE 336. UNITED STATES ANTI-OBESITY DRUGS MARKET SIZE, BY DOSAGE FORM, 2025-2032 (USD MILLION)
  • TABLE 337. UNITED STATES ANTI-OBESITY DRUGS MARKET SIZE, BY INJECTABLES, 2018-2024 (USD MILLION)
  • TABLE 338. UNITED STATES ANTI-OBESITY DRUGS MARKET SIZE, BY INJECTABLES, 2025-2032 (USD MILLION)
  • TABLE 339. UNITED STATES ANTI-OBESITY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 340. UNITED STATES ANTI-OBESITY DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 341. UNITED STATES ANTI-OBESITY DRUGS MARKET SIZE, BY INJECTABLE, 2018-2024 (USD MILLION)
  • TABLE 342. UNITED STATES ANTI-OBESITY DRUGS MARKET SIZE, BY INJECTABLE, 2025-2032 (USD MILLION)
  • TABLE 343. UNITED STATES ANTI-OBESITY DRUGS MARKET SIZE, BY END USER, 2018-20